Iniparib (INN, formerly known as BSI 201 ) is a drug candidate for cancer treatment. Initially believed to act as an irreversible inhibitor of PARP1 (hence, PARP inhibitors) and possibly other enzymes through covalent modification, but its effect on PARP later proved untrue. It underwent clinical trials for the treatment of certain types of breast cancer, but was discontinued after a disappointing phase III trials trial.
Video Iniparib
History
Iniparib is the first suspected PARP inhibitor to initiate phase III clinical trials. The first is for breast cancer, the other is for squamous cell lung cancer. Preliminary results in June 2009 in triple-negative breast cancer were promising. Subsequent results showed an increase in the average survival of triple-negative breast cancer patients from 7.7 to 12.2 months.
In 2009, the FDA began accelerating the adoption of this new drugparib for triple-negative breast cancer. However, the phase III results revealed in January 2011 were disappointing.
Iniparib is also studied as a potential chemotherapy agent in the fight against malignant glioma, including glioblastoma. Gliomas are a formidable (non-metastatic) primary brain tumor that currently has limited effective therapies, especially for patients whose tumors are in an unoperable location of the brain, such as the inside of the brainstem.
During the American Society of Clinical Oncology 2013 conference, Sanofi revealed that thisparib failed to help lung cancer patients in a late-stage trial, prompting the company to end its research into a compound that once was promising and cost $ 285 million.
Maps Iniparib
References
Source of the article : Wikipedia
0 Comments